The Use of Omalizumab in Food Oral Immunotherapy.
Arch Immunol Ther Exp (Warsz)
; 65(3): 189-199, 2017 Jun.
Article
em En
| MEDLINE
| ID: mdl-27628022
ABSTRACT
Food allergy is an important health issue that affects up to 8 % of the population. The management of allergic patients involves allergen avoidance and prompts the treatment of accidental reactions, as no curative treatment is available so far in routine practice. Oral immunotherapy (OIT) is a promising therapeutic alternative, but it is associated with frequent allergic reactions and cost-effectiveness issues. In hopes of reducing such reactions, a number of trials have used omalizumab, an anti-IgE monoclonal humanized antibody, as adjunctive therapy in OIT. The allergens studied in these omalizumab-enabled OIT trials include peanuts, milk, eggs, or mixes of multiple foods. In this article, we review the major findings from these studies and discuss potential benefits and issues related to omalizumab-enabled OIT. Results from the previous trials suggest that the use of omalizumab could potentially lead to safer and more efficient OIT protocols, by reducing the number and severity of reactions, and increasing allergen tolerance threshold. While more evidence is needed with regard to the maintenance of the long-term tolerance after OIT, omalizumab's potential immunomodulatory role could be of benefit. More studies are needed to further document this new indication for omalizumab.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Contexto em Saúde:
3_ND
Problema de saúde:
3_zoonosis
Assunto principal:
Imunoglobulina E
/
Alérgenos
/
Dessensibilização Imunológica
/
Anticorpos Monoclonais Humanizados
/
Omalizumab
/
Hipersensibilidade Alimentar
/
Anafilaxia
Tipo de estudo:
Etiology_studies
/
Guideline
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Arch Immunol Ther Exp (Warsz)
Ano de publicação:
2017
Tipo de documento:
Article
País de afiliação:
Canadá